| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-635 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2002-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc3946a059cb8199b1bfb0186b003a8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_856dae3f3c59ed2668654f6cd4b21255
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e8077552fbc37c7c25d2c586328e1c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f762ba4ccc267c2feafdc1aca53c2346 |
| publicationDate |
2003-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2003119744-A1 |
| titleOfInvention |
PSP-94: use for treatment of hypercalcemia and bone metastasis |
| abstract |
The present invention discloses the use of PSP-94 for treating a patient suffering from hypercalcemia of malignancy. Prostate secretory protein of 94 amino acids (PSP-94) is known to serve as prognostic marker in hormone-dependent prostate. In the current study the effect of PSP-94 on prostate cancer growth, metastases to the skeleton and hypercalcemia of malignancy was examined. A marked dose-dependent decrease in primary tumor volume was seen in experimental animals receiving PSP-94. Furthermore, while control animals routinely developed hypercalcemia due to PTHrP production, treatment with PSP-94 led to a near normalization of plasma calcium and a marked reduction in PTHrP production as determined by radioimmunoassay and immunohistochemistry. Results obtained demonstrate the ability of PSP-94 to be an effective treatment modality for prostate cancer. Furthermore, decrease in plasma PTHrP and calcium levels can serve as useful biochemical markers for monitoring the efficacy of this novel anti-tumor agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005096273-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021369769-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008182777-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005148514-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020093069-A1 |
| priorityDate |
2001-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |